Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

J Thorac Oncol. 2017 Nov;12(11):e182-e184. doi: 10.1016/j.jtho.2017.07.021.

Authors

Lucien Marchand¹, Valérie Paulus², Nicole Fabien³, Maurice Pérol², Charles Thivolet⁴, Julien Vouillarmet⁴, Pierre Saintigny²

Affiliations

¹ Department of Endocrinology and Diabetes, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France. Electronic address: [email protected].
² Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
³ Department of Immunology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France.
⁴ Department of Endocrinology and Diabetes, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France.

PMID: 29074210
DOI: 10.1016/j.jtho.2017.07.021

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acute Disease
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / pharmacology
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / pharmacology
Diabetes Mellitus / chemically induced*
Diabetes Mellitus / pathology
Humans
Hypophysitis / chemically induced*
Hypophysitis / pathology
Lung Neoplasms / complications*
Lung Neoplasms / pathology
Male
Middle Aged
Nivolumab

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Nivolumab